The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

• Sponsor: Ankara City Hospital Bilkent (Other)
• Overall Status: Completed
• CT.gov ID: NCT04799600
• Collaborator: (none)
• Enrollment: 158
• Location: 1
• Actual Duration (Months): 10
• Patients Per Site Per Month: 15.9

Study Details

Study Description

Brief Summary

Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.

Condition or Disease	Intervention/Treatment	Phase
COVID19; Acute Renal Failure	Other: BRESCİA-COVİD Respiratory Severity Scale

Study Design

• Study Type: Observational
• Actual Enrollment: 158 participants
• Observational Model: Cohort
• Time Perspective: Cross-Sectional
• Official Title: The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
• Actual Study Start Date: Sep 1, 2020
• Actual Primary Completion Date: Jun 15, 2021
• Actual Study Completion Date: Jul 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Acute Renal Failure in ICU COVID-19 Patients with Acute Renal Failure in ICU	Other: BRESCİA-COVİD Respiratory Severity Scale; KDIGO acute renal failure score BRESCİA-COVID Respiratory Severity Score

Outcome Measures

Primary Outcome Measures

1. KDIGO criteria [6 months]

   KDIGO Criteria stage 1: Increase in SCr by ≥ 0.3 mg/dL within 48 hours or increase in SCr 1.5 to 1.9 times baseline which is known or presumed to have occurred within the prior 7 days Stage 2: 2.0 to 2.9 multiplied by baseline SCr; Stage 3: 3.0 or more multiplied by baseline; increase in SCr ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage.

2. BRESCIA-COVID RESPIRATORY SEVERITY SCALE (BCRSS) scores [6 months]

   The BCRSS score (between level 0-8) is calculated from "www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm" according to the severity of COVID disease , respiratory rate, PaO2 level, chest x-ray, and clinical status.

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Patients hospitalized in the intensive care unit diagnosed with COVID-19 will include in the study.

Exclusion Criteria:

there is no exclusion criteria

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ankara City Hospital	Ankara		Turkey	06800

Sponsors and Collaborators

• Ankara City Hospital Bilkent

Investigators

• Principal Investigator: betül aytaç, MD, ankara ch bilkent

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: ismail aytaç, medical doctor, Ankara City Hospital Bilkent
• ClinicalTrials.gov Identifier: NCT04799600
• Other Study ID Numbers: E1-20-1443
• First Posted: Mar 16, 2021
• Last Update Posted: Jul 27, 2021
• Last Verified: Jul 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by ismail aytaç, medical doctor, Ankara City Hospital Bilkent: COVID19; Acute Renal Failure
• Additional relevant MeSH terms: COVID-19; Renal Insufficiency; Acute Kidney Injury

Study Results

No Results Posted as of Jul 27, 2021